RESUMO
Chimeric antigen receptor (CAR)-T cell immunotherapy have developed for nearly two decades and achieved great clinical success in the treatment of hematological malignancies. Efficacy monitoring and toxicity management of CAR-T cell immunotherapy are essential steps to ensure safety and improve overall survival in multicenter clinical trials and commercialized treatments. CAR-T cell immunotherapy related biomarkers can be used as an indicator of patient baseline characteristics, tumor biology, and CAR-T cell function. Besides, side effects during treatment can also be assessed by the biomarkers.
RESUMO
Circulating tumor cells (CTCs) are defined as tumor in bloodstream or metastasis-derived cells.It can monitor the progress of metastatic diseases and may play an important role in determining tailored therapies of advanced cancer.The new blood marker technology may be the starting point of a clinical trial to study the pathogenesis of gastrointestinal tumors and the diagnosis and prognosis of gastrointestinal neoplasms and efficacy monitoring in the fulture.In the paper,role of CTCs in the diagnosis,prognosis of gastrointestinal neoplasms,monitoring efficacy and its prospect are reviewed.